Hallmarks and correlates of effective adoptive cell immunotherapy for cancer
- 2 June 2026
- journal article
- review article
- Published by Springer Nature in Nature Reviews Immunology
- Vol. 26 (11) , 799-816
Abstract
Cancer immunotherapies have shown promise and success in a number of different types of tumours, yet many solid epithelial tumours remain recalcitrant. Somatic mutations in tumour cells can lead to the expression of neoantigens, which are potent targets of the human antitumour immune response. These can be targeted through adoptive cell transfer (ACT) of neoantigen-specific T cells, including tumour-infiltrating lymphocytes (TILs) or T cell receptor (TCR)-engineered T cells (TCR-T cells), an approach that has been shown to achieve tumour regression in patients with different types of metastatic solid tumours including melanoma, breast and gastrointestinal cancer. Immunogenomics, systems immunology and genome editing now provide multidisciplinary tools to design cell therapies against solid cancer. Here, we review historical efforts and our current conceptual understanding of ACT using TILs or TCR-T cells. Moreover, we highlight emerging correlates of response to ACT and novel strategies that integrate tumour immunology, cancer genomics, computational biology and T cell engineering for the development of next-generation cellular immunotherapies.Keywords
This publication has 268 references indexed in Scilit:
- Transcriptomic profiles of neoantigen-reactive T cells in human gastrointestinal cancersCancer Cell, 2022
- Myeloid antigen-presenting cell niches sustain antitumor T cells and license PD-1 blockade via CD28 costimulationCancer Cell, 2021
- Identifying and Targeting Human Tumor Antigens for T Cell-Based Immunotherapy of Solid TumorsCancer Cell, 2020
- The Quantification of Antigen-Specific T Cells by IFN-γ ELISpot2020
- 1052P Genetic modification of Iovance’s TIL through TALEN-mediated knockout of PD-1 as a strategy to empower TIL therapy for cancerAnnals of Oncology, 2020
- HLA class I alterations in breast carcinoma are associated with a high frequency of the loss of heterozygosity at chromosomes 6 and 15Immunogenetics, 2018
- Tumor-Residing Batf3 Dendritic Cells Are Required for Effector T Cell Trafficking and Adoptive T Cell TherapyCancer Cell, 2017
- Multiple mechanisms generate HLA class I altered phenotypes in laryngeal carcinomas: high frequency of HLA haplotype loss associated with loss of heterozygosity in chromosome region 6p21Cancer Immunology, Immunotherapy, 2002
- Improved detection of melanoma antigen‐specific T cells expressing low or high levels of CD8 by HLA‐A2 tetramers presenting a Melan‐A/Mart‐1 peptide analogueInternational Journal of Cancer, 2001
- Generation of Melanoma-Specific, Cytotoxic CD4+ T Helper 2 Cells: Requirement of both HLA-DR15 and Fas Antigens on Melanomas for Their Lysis by Th2 CellsCellular Immunology, 2001